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Original ArticleNatural Exon Skipping Sets the Stage
for Exon Skipping as Therapy
for Dystrophic Epidermolysis Bullosa
Jeroen Bremer,1,2 Elisabeth H. van der Heijden,1 Daryll S. Eichhorn,2 Rowdy Meijer,3 Henny H. Lemmink,1
Hans Scheffer,3 Richard J. Sinke,1 Marcel F. Jonkman,2 Anna M.G. Pasmooij,2 and Peter C. Van den Akker1,2
1Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; 2Department of Dermatology, University of
Groningen, University Medical Center Groningen, Groningen, the Netherlands; 3Department of Human Genetics, Radboud University Nijmegen Medical Centre,
Nijmegen, the NetherlandsDystrophic epidermolysis bullosa (DEB) is a devastating
blistering disease affecting skin and mucous membranes. It is
caused by pathogenic variants in the COL7A1 gene encoding
type VII collagen, and can be inherited dominantly or reces-
sively. Recently, promising proof-of-principle has been shown
for antisense oligonucleotide (AON)-mediated exon skipping
as a therapeutic approach for DEB. However, the precise
phenotypic effect to be anticipated from exon skipping, and
which patient groups could beneﬁt, is not yet clear. To answer
these questions, we studied new clinical and molecular data on
seven patients from the Dutch EB registry and reviewed the
literature on COL7A1 exon skipping variants. We found that
phenotypes associated with dominant exon skipping cannot
be distinguished from phenotypes caused by other dominant
DEB variants. Recessive exon skipping phenotypes are gener-
ally relatively mild in the spectrum of recessive DEB. Therefore,
for dominant DEB, AON-mediated exon skipping is unlikely to
ameliorate the phenotype. In contrast, the overall severity of
phenotypes associated with recessive natural exon skipping
pivots toward the milder end of the spectrum. Consequently,
we anticipate AON-mediated exon skipping for recessive
DEB caused by bi-allelic null variants should lead to a clinically
relevant improvement of this devastating phenotype.Received 16 May 2019; accepted 10 September 2019;
https://doi.org/10.1016/j.omtn.2019.09.009.
Correspondence: Jeroen Bremer, Department of Genetics, University of Gronin-
gen, University Medical Center Groningen, P.O. Box 30.001, 9700 Groningen, the
Netherlands.
E-mail: j.bremer@umcg.nlINTRODUCTION
Dystrophic epidermolysis bullosa (DEB) is a monogenic, heritable
skin disease caused by pathogenic variants in the COL7A1 gene,
which encodes the epidermal-dermal adhesion protein type VII
collagen. DEB, which can be inherited either autosomal dominantly
(DDEB; OMIM: 131750) or recessively (RDEB; OMIM: 226600), is
characterized by blistering of skin and mucosae upon the slightest
trauma.1 The severity of DEB is generally well correlated to the
quantity and functionality of type VII collagen that is expressed.2
Phenotypic severity ranges from involving only nails (DDEB-na) to
generalized and severe blistering and scarring (RDEB-gen sev). In
general, the prognosis of DDEB is much better than that of RDEB.
Patients suffering from RDEB-gen sev often die at the age of 30–40
years because of complications of blister formation and aggressiveMolecular Thera
This is an open access article under the CC BY-NC-squamous cell carcinomas evoked by the complete absence of type
VII collagen.3 Patients suffering frommilder DEB phenotypes in gen-
eral have a normal lifespan. Currently, several therapeutic strategies
are under investigation, although no curative therapy has been trans-
lated into the clinic and treatment remains primarily symptomatic.4
Type VII collagen is an extracellular matrix component that secures
the epidermis to the papillary dermis by forming anchoring ﬁbrils.
The 118 exons of COL7A1 are ﬁrst translated into a pro-a1-type
VII collagen molecule, which comprises an 145-kDa amino-termi-
nal non-collagenous 1 domain (NC-1), an 145-kDa central triple-
helix domain (THD), and an 30-kDa C-terminal non-collagenous
2 domain (NC-2). The NC-1 domain contains regions that are essen-
tial for interactions to binding partners like type IV collagen and lam-
inin-332.5,6 The THD contains a highly repetitive glycine-Xaa-Yaa
amino acid sequence (Gly-X-Y) that is essential for proper triple-helix
formation.7 The THD, encoded by exons 29–112, is interrupted 19
times, with the ﬂexible, so-called intrinsically disordered, central
39-amino acid “hinge region” being the major interruption.8 Post-
translational modiﬁcations subsequently lead to triple-helix forma-
tion of three pro-a1 chains, followed by cleavage of the NC-2 domain
and antiparallel dimerization. Extracellularly, the antiparallel dimers
aggregate laterally to form anchoring ﬁbrils.
DEB-causing variants are widely spread throughout the 118 exons of
the COL7A1 gene. In total, more than 700 DEB-causing variants in
the COL7A1 gene have been reported.9,10 Variants that lead to domi-
nant phenotypes are exclusively located in the THD, where exon 73 is
a hotspot.11 A single glycine substitution in the THD can impair the
ability to form stable triple helices and is the main cause of DDEB.12
RDEB-causing variants, on the other hand, are found throughout thepy: Nucleic Acids Vol. 18 December 2019 ª 2019 The Authors. 465
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Nucleic Acidsentire gene. RDEB-gen sev is caused by bi-allelic null variants,
whereas milder RDEB phenotypes are due to at least one allele capable
of producing an, albeit imperfect, pro-a1 type VII collagen. The pre-
cise phenotype is determined by the combination of both alleles and
the dynamic interplay with the individual’s genetic background.13
Multiple COL7A1 variants are located in splicing signals and can
disturb normal splicing.9,10 Several lead to an entire exon being
spliced out from the pre-mRNA, i.e., the exon is skipped. Of the
118 COL7A1 exons, 107 are “in-frame,” and skipping these exons
will still leave the reading frame intact. Because the exons of the
COL7A1 gene are very small (27–201 bp), with an average length of
54 bp (NM_000094.3), exon skipping would exclude only short
sequences from the mRNA and lead to a type VII collagen that is
predicted to be only slightly shorter.
The small exons, in combination with the highly repetitive sequence
of the THD, make COL7A1 an ideal candidate for antisense oligonu-
cleotide (AON)-mediated exon skipping.14 AON-mediated exon
skipping aims to bypass disease-causing COL7A1 variants by
removing the mutant exon and thereby restoring the expression of
a functional type VII collagen. The strong correlation between type
VII collagen expression and the clinical phenotype predicts that the
slightest increase in type VII collagen deposition at the basement
membrane zone (BMZ) should have marked effects on the pheno-
type.2 Recently, we have shown encouraging pre-clinical results
with AON-mediated exon skipping as a systemic therapeutic
approach for RDEB.15 We also showed that exon 13 and 105-skipped
type VII collagen retains functionality comparable with wild-type.14
The precise beneﬁt of exon skipping therapy, and which patient
groups would beneﬁt from it, is, however, not yet clear. We hypoth-
esized that studying patients in which COL7A1 variants induce natu-
ral exon skipping would shed light on the therapeutic potential of
AON-mediated exon skipping. We therefore scrutinized the Dutch
Epidermolysis Bullosa (EB) registry for natural exon skipping vari-
ants and reviewed the literature on this class of variants. The overview
of the natural exon skipping variants presented here sets the stage for
further work on AON-mediated exon skipping therapy for DEB.
RESULTS
Exon Skipping Variants Found in the Dutch EB Registry
There is a large cohort of DEB patients registered at the Center for
Blistering Diseases, University Medical Center Groningen (the
Netherlands). In June 2018, there were 176 DEB patients, of which
100 had a dominant and 76 a recessive form of DEB. Of these 176 pa-
tients, 26 carried variants located in putative splice sites, of which 7
were conﬁrmed to induce in-frame exon skipping at the RNA level
by RT-PCR. Six resulted in skipping of an out-of-frame exon, and 13
resulted in aberrant splicing other than skipping an entire exon. A com-
parison of the clinical presentation and immunoﬂuorescence (IF) stain-
ing between the patients carrying those seven in-frame exon skipping
variants showed that the phenotypic severity and type VII collagen
expression levels at the BMZ varied markedly (Figure 1). The seven
patients and their families are described brieﬂy below.466 Molecular Therapy: Nucleic Acids Vol. 18 December 2019The father and son of family 1 (EB-072) both presented with gener-
alized blistering upon slight trauma, constituting a typical generalized
DDEB (DDEB-gen) phenotype; they carried the heterozygous variant
c.6181-6T>G in intron 73. It was predicted that this variant would
disrupt normal splicing and consequently induce exon 74 skipping,
which was indeed conﬁrmed at the RNA level (Figure S1). Because
in-frame skipping of exon 74 has been described as exerting a domi-
nant-negative effect over the wild-type allele and causing DDEB,16 we
concluded this natural skipping of exon 74 would explain their DDEB
phenotype and inheritance pattern.
The father and daughter of family 2 (EB-152) presented with a
DDEB-gen phenotype caused by a heterozygous deletion of the last
two nucleotides of exon 87 (c.6899_6900del). This variant abolishes
the intron 87 splice donor site, which results in the deletion of the
entire exon 87 (Figure S1). A dominant-negative effect of in-frame
exon 87 skipping has been described, and this explains their DDEB
phenotype.17–30
The index patient in family 3 and her father (EB-156) presented with
a typical DDEB-acral (DDEB-ac) phenotype (Figure 1): nail dystro-
phy and blisters predominantly on hands, knees, and feet. An
intronic, 21-bp deletion (c.6832-23_6832-3del) was identiﬁed hetero-
zygously in intron 86 and was predicted to result in the loss of the
intron 86 splice acceptor site. RT-PCR indeed conﬁrmed in-frame
exon 87 skipping in this family, explaining their dominant phenotype
(Figure S1).
The index patient in family 4 (EB-339) presented with generalized
blistering upon minor trauma (DDEB-gen). The heterozygous
variant c.7894-2A>G in intron 107 was found both in the patient
and his affected mother, and it was predicted to lead to the loss of
the intron 107 splice acceptor site. RNA analysis conﬁrmed in-frame
skipping of exon 108 (Figure S1). Because no other variant was
found and skipping of exon 108 has been described to cause a
dominantly inherited phenotype,31 this most likely explains their
phenotype.
DNA analysis of the index patient in family 5 (EB-052) showed com-
pound heterozygosity for the maternal, synonymous variant
c.4011G>A in exon 33 and the paternal c.7769G>A (p.(Gly2590Asp))
variant in exon 104. The maternal variant at the last position of exon
33 caused skipping of the exon, as shown by RT-PCR (Figure S1). The
index patient presented with blistering after minor trauma from birth
and the RDEB-gen intermed (RDEB-generalized intermediate)
phenotype. No skin abnormalities were observed in the parents on
clinical examination, indicating a recessive effect of the exon 33
skipping variant.
The index patient in family 6 (EB-363) has two unaffected
parents and presented with a recessively inherited DEB phenotype
(RDEB-gen intermed), characterized by generalized blistering of
skin andmucosa upon the slightest trauma, with scar tissue formation
and loss of nails. Variant analysis identiﬁed the c.1573C>T
Figure 1. Clinical and Molecular Phenotypes of
Seven DEB Patients Associated with Natural Exon
Skipping
Left column: DEB clinical phenotypes associated with
natural exon skipping depicted by representative photo-
graphs of the hands. Immunofluorescence (IF) staining
(40) of type VII collagen at the basement membrane
zone (BMZ) is shown compared with control (middle
columns). Right column: IF detail of the BMZ revealing
retention of type VII collagen by basal keratinocytes
(asterisks) in patients 1–4 and 6. Scale bars: 25 mm.
www.moleculartherapy.org(p.Arg525*) null variant in exon 12 on the maternal allele and the
c.8227-1G>C transversion in intron 110 on the paternal allele.
RT-PCR revealed that the paternal variant resulted in the in-frameMolecular Therapskipping of exon 111 (Figure S1). Because no
DEB features could be detected in the father
on clinical examination, the in-frame deletion
of exon 111 must act recessively, as described
previously.32
The parents in family 7 were unaffected, but the
affected child presented with an RDEB-gen in-
termed phenotype caused by a homozygous
mutation that affected the normal splicing of
exon 20. RNA analysis revealed three tran-
scripts: (1) in-frame skipping of exon 20, (2)
alternative splicing using a cryptic splice donor
in intron 20 resulting in an out-of-frame tran-
script, and (3) the wild-type transcript (Fig-
ure S1). Unfortunately, clinical and molecular
details cannot be shown because, despite oral
consent being given, we have not received writ-
ten consent.
Exon Skipping Variants Described in the
Literature
Our literature search revealed another 20
COL7A1 variants that were conﬁrmed at the
RNA level to induce in-frame exon skipping,
bringing the total to 27 (summarized in Table 1
and Figure 2). This represents 3%–4% of the
approximately 700 disease-associated variants
that have been described for the COL7A1
gene. These 27 variants were involved in either
dominantly (15/27) or recessively (12/27)
inherited phenotypes.
Mechanisms Underlying Exon Skipping
The mechanism underlying exon skipping for
all variants is the disruption of constitutional
splice signal sequences. The lack of strong,
cryptic splice signals in the vicinity of the dis-rupted constitutive splice signals likely explains why skipping of
entire exons occurs instead of other alternative splicing patterns.33
Out of the 27 natural exon skipping variants, 23 were located in splicey: Nucleic Acids Vol. 18 December 2019 467
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DDEB-ac, DDEB-acral; DDEB-gen, DDEB-generalized; DDEB-pr, DDEB-pruriginosa; DDEB-pt, DDEB-pretibial; DDEB-u, DDEB-unknown (mild form); NA, not applicable; NF, not found; RDEB-ac, RDEB-acral; RDEB-
gen intermed, RDEB-generalized intermediate; RDEB-gen sev, RDEB-generalized severe; RDEB-pr, RDEB-pruriginosa; RDEB-pt, RDEB-pretibial.
aSome of the DNA variants have been shown to lead to multiple splice variants at the RNA level. For reasons of readability, only splice variants deduced to lead to protein expression are shown between brackets. For instance,
p.[ =, Gly1925_Pro1940del]) indicates that the DNA variant c.5820G>A in exon 70 leads to two functional protein molecules, as deduced from RNA analysis: a wild-type protein isoform (p. = ) and an isoform from which
exon 70 is skipped (p.Gly1925_Pro1940del). More information on other non-functional splice variants can be found in the references cited. “c. =” means wild-type allele.
bHeterogeneous exon skip indicates there will be a combination of wild-type and skipped product. Mutant products (caused by a missense mutation) are mentioned explicitly, where present.
cOnly the effect on the protein level and phenotype is provided, because no written consent was obtained.


























































Figure 2. Overview of the COL7A1 Gene and Natural Exon Skipping Variants
The upper pane shows an overview of the type VII collagen protein with the noncollagenous-1 (NC1), triple-helix (THD), and noncollagenous-2 domains (NC2). Dominant and
recessive variants leading to natural exon skipping are indicated above and below the pane, respectively. Interruptions of the Gly-X-Y structure are indicated in gray to scale.
The NC-2 cleavage site is indicated (scissors). In the middle pane, the upper bar shows all 118 exons to scale with the corresponding nucleotide (Nt) and amino acid (AA)
numbers; colors correspond to the respective protein domains encoded. The second bar shows the same exon structure of COL7A1 to scale, this time indicating the exons
involved in natural exon skipping (black), other in-frame exon skipping candidates (white), and “non-skippable,” out-of-frame exons (gray). The lower pane shows the relative
location of crucial domains. CMP, cartilage-matrix protein motif; C/P cysteine/proline-rich motif; FN-III, fibronectin-III-like domains 1–9; hinge, intrinsically disordered hinge
region; KM, Kunitz-motif-like domain; SP, signal peptide; VWA, von Willebrand factor A-like domain.
Molecular Therapy: Nucleic Acidssites. A higher number of variants was found in splice donor sites than
acceptor sites: 14 versus 9, respectively. The higher prevalence of
donor site variants than acceptor site variants has been reported in
a large cohort of splice-site variants.33 There appeared to be no differ-
ence in mechanism between dominant and recessive variants. The
other 4/27 variants exerted their exon skipping effect through dis-
rupting predicted exonic splicing enhancer sequences (ESEs): two
small deletions and one single base substitution located in an ESE
in the center of exon 87.17–19 ESEs are the class of splicing signals
that AONs aim to target in order to induce exon skipping.
Genotype-Phenotype Correlation
Dominant Exon Skipping
In total, 15 exon skipping variants were found to be associated with
dominant phenotypes (17 patients). The overall clinical heterogeneity
observed in dominant exon skipping cases was similar to that
observed for dominant glycine substitutions.12 The dominant pheno-
types that were observed with skipping of exons 71, 74, 87, and 108
almost cover the complete DDEB phenotypic spectrum from acral,
pretibial, pruriginosa, to DDEB-gen. The phenotypic spectrum of
DDEB phenotypes caused by exon skipping could not be explained
by differences in the amount of detectable type VII collagen at the
BMZ, because this was reported to be normal for 13 out of 15 variants.
The only two variants for which type VII collagen expression was re-
ported to be abnormal led to slightly reduced and strongly reduced
expression, and the acral and pruriginosa forms of DDEB, ﬁtting
in the middle of the DDEB-phenotypic spectrum, respectively.470 Molecular Therapy: Nucleic Acids Vol. 18 December 2019Dominant skipping of exons 71, 74, and 108 resulted in the pretibial,
pruriginosa, and generalized forms of DDEB, respectively. Skipping
of exon 87 was associated with a variety of phenotypes, leading
to DDEB-ac, DDEB-pretibial (DDEB-pt), DDEB-pruriginosa
(DDEB-pr), and DDEB-gen (Table 1). To some extent, dominant
skipping leads to the retention of type VII collagen in basal keratino-
cytes, as shown by IF (Figure 1).
In contrast with recessive exon skipping variants that were found
throughout the gene, and in concert with classical DDEB-causing
glycine substitutions, the 15 dominant exon skipping variants were
located exclusively within the THD, predominantly in its C-terminal
region. More speciﬁcally, they were all located in, or in the vicinity of,
interruptions in the collagenous structure: (1) either in or directly
adjacent to the hinge region (exons 71 and 74, respectively), or in
close proximity to (2) interruptions in the THD or (3) the NC-2
domain (exons 87 and 108, respectively). Exon 87 (Figure 3) repre-
sents a hotspot for dominant natural exon skipping variants: 10
different variants having been identiﬁed to date that lead to skipping
of exon 87. Exon 87 precedes a short imperfection in the collagenous
structure, located 2 amino acids downstream in exon 88, and a larger
imperfection of 18 amino acids farther downstream in exon 89.
Recessive Exon Skipping
Recessive exon skipping variants were scattered throughout the gene,
and there was no apparent distribution pattern related to interrup-
tions of the glycine repeat of the THD (Figure 2). Exons 70 and 73
Figure 3. Variants Causing Natural Exon 87 Skipping
Exon 87 and its flanking intronic sequences showing vari-
ants that cause natural exon skipping in red. Predicted
binding strength of exonic splice enhancers is shown in the
lower graph. AU, arbitrary units.
www.moleculartherapy.orgare located immediately upstream and downstream of the hinge re-
gion (encoded by exons 71 and 72). Exon 111 contains a minor inter-
ruption and is located only 15 amino acids upstream of the NC-2
domain, whereas exons 33, 53, 95, 106, and 107 are separated by
18, 48, 15, 108, and 90 amino acids from interruptions in the glycine
repeat, respectively.
In total, 12 exon skipping variants (20 patients) were found to be asso-
ciated with recessive phenotypes. All RDEB phenotypes were
observed: i.e., acral, pretibial, generalized intermediate, and even
the generalized severe form of RDEB. Fourteen patients had pheno-
types milder than the most severe phenotype (2 patients had acral,
1 pruriginosa, 1 pretibial, and 10 gen intermed RDEB), whereas six
patients were reported as having RDEB-generalized severe. In
contrast with dominant exon skipping variants where, in general,
normal expression levels of type VII collagen were observed, recessive
variants resulted in varying expression levels ranging from complete
absence to normal (Table 1). As expected, type VII collagen expres-
sion correlated well with phenotypic severity (Figure S2). Normal
type VII collagen expression was seen in patients with acral, pretibial,
and generalized intermediate forms, whereas it was “slightly reduced”
or “reduced” in patients with generalized intermediate forms of
RDEB. Strongly reduced expression was observed in generalized in-
termediate and generalized severe forms of RDEB. Complete absence
of type VII collagen expression was reported in only one case with
generalized severe RDEB. Complete absence of type VII collagen
expression levels was an unexpected ﬁnding given that the exon skip-
ping mutation was expected to preserve protein production. This
could be explained by low-grade exon 107 skipping, resulting in un-
detectable levels of type VII collagen, or an uncovered null mutation
in cis with the exon 107 skipping variant.
Of particular interest, with regard to exon skipping therapy, is variant
1 (Table 1). The respective patient carried the variant c.2005C>T
(p.Arg669*) in exon 15 and a frameshift variant c.6311_6312del
(p.Ser2104Trpfs*12) in exon 76. This genotype was predicted to go
with complete absence of type VII collagen and, therefore, the most
severe RDEB-gen sev phenotype. However, the patient also carried
the rare single-nucleotide variant c.1907G>T (rs116005007,
minor allele frequency 0.22%: T = 0.0022/11; 1000 Genomes;Molecular Therahttps://www.ncbi.nlm.nih.gov/variation/tools/
1000genomes/) in cis with the c.2005C>T
variant. This variant, located in the ﬁrst codon
of exon 15, was subsequently shown to modify
splicing of exon 15, leading to in-frame skipping
of exon 15, thus bypassing the null variant and
resulting in the synthesis of some functionaltype VII collagen, which explained the substantially milder pheno-
type. The carrier parent had no visible DEB features.
In contrast with 14 patients with milder phenotypes, 6 out of 20 cases
from the literature were described as having a severe generalized
RDEB phenotype (Table 1). In all six cases, type VII collagen expres-
sion was either strongly reduced or completely absent. Five of the six
cases were compound heterozygous for a null variant in transwith the
exon skipping variant. In contrast, of the 14 patients with milder phe-
notypes, only 6 carried a null allele in trans with the exon skipping
variant, and 8 had two functional alleles (either a homozygous exon
skipping variant or a combination of the exon skipping variant
with a missense variant). Only one patient with RDEB-gen sev carried
the exon skipping variant homozygously. This homozygous variant,
c.7929+1G>A, was associated with strongly reduced expression of
an exon 106-skipped type VII collagen. Unfortunately, detailed indi-
vidual data were not available to assess and compare the expression
levels and the phenotypes of these cases.
DISCUSSION
We investigated the genotype-phenotype correlation of natural exon
skipping variants found in patients with DEB to anticipate the thera-
peutic effect of AON-mediated exon skipping. We included a series of
sevenCOL7A1 exon skipping variants from the Dutch EB registry and
20 additional exon skipping variants from the literature. For all 27
variants, exon skipping had been conﬁrmed at the RNA level.
Our review shows that natural exon skipping variants act either
autosomal dominantly or recessively (Figure 2). Altogether, the
phenotypic spectrum caused by dominant exon skipping reﬂects
the normal phenotypic spectrum of DDEB. In contrast, recessive
exon skipping generally leads to a phenotype on the milder end of
the RDEB-phenotypic spectrum. However, the expression levels of
the skipped proteins appear to be very important for the precise
phenotypic outcome. Assessing the exact correlation between
expression of the skipped type VII collagen and the clinical pheno-
types was, however, not straightforward, because there was consid-
erable variation in reported protein expression levels as determined
by IF. This is at least partly due to the fact that patients were
analyzed in different clinics, by different clinicians, and at differentpy: Nucleic Acids Vol. 18 December 2019 471
Molecular Therapy: Nucleic Acidsages. Although systematic analysis at the RNA and protein levels for
all natural exon skipping mutations was not possible, the general
pattern that emerged was that the expression levels of type VII
collagen lacking an exon in either the NC-1 domain or the THD
correlated well to the severity of the phenotype, comparable with
other recessive mutations. In addition, individual cases show that
low levels of expression of type VII collagen can already dramati-
cally ameliorate the phenotype.
Our study therefore sets the stage for AON-mediated exon skipping,
because these results indicate that exon skipping will most likely not
have a beneﬁcial effect on DDEB caused by glycine substitutions. Un-
less mutation-speciﬁc, AON-mediated exon skipping will most likely
skip both mutant and wild-type exons and, if this process were 100%
efﬁcient, would change a heterozygous, dominant-negative glycine
substitution into a homozygous exon skipping mutation. Although
this would not have the problem of dominant-negative interference,
homogenously expressing exon-skipped type VII collagen is not
expected to improve the DDEB phenotype. This is illustrated by 10
patients who homogeneously expressed type VII collagen lacking
exons 15, 19, 20, 33, 53, 87, 106, 107, or 111 (Table 1) and whose phe-
notypes were more severe than DDEB phenotypes at the severe end of
the spectrum. Although this could partly be due to lower-than-
normal type VII collagen expression andmay not be true for all exons,
the natural exon skipping data so far do not provide evidence that
exon skipping would beneﬁt DDEB phenotypes. Furthermore,
because AON-mediated exon skipping will be signiﬁcantly less efﬁ-
cient than 100% and cannot be administered continuously, treatment
of DDEB with exon skipping will likely introduce an exon-skipped
allele in addition to the wild-type and mutant alleles, which might
even worsen the phenotype. Therefore, other therapeutic strategies
seem to be more appropriate for DDEB, such as allele-speciﬁc knock-
down using siRNAs.34
In contrast, although exon skipping might not work for all exons, as
illustrated by the cases with a severe generalized phenotype, AON-
mediated exon skipping could be beneﬁcial for RDEB-gen sev
patients, where complete absence of type VII collagen is the cause
of disease. Two cases well illustrate what exon skipping as a therapeu-
tic approach aims to achieve, i.e., bypassing a null variant by
excluding its residential exon. The null variant c.2005C>T in exon
15 was rescued by the rare DNA variant c.1907G>T in the same
exon, which causes skipping of exon 15 and thus bypasses the null
variant.35 Although the level of expression of type VII collagen lack-
ing exon 15 was still rather low, the co-occurrence of both variants on
the same allele led to a milder than expected RDEB-gen intermed
phenotype. The second case had the c.2471dup variant in exon 19,
which was predicted to cause a frameshift with premature termina-
tion codon and the most severe phenotype. However, skipping of
exon 19 led to moderate levels of exon 19-skipped type VII collagen,
and a surprisingly mild RDEB-gen intermed phenotype.36 These exon
15 and exon 19 skipping cases show that the introduction of even
small amounts of skipped type VII collagen can result in signiﬁcantly
less severe phenotypes.472 Molecular Therapy: Nucleic Acids Vol. 18 December 2019Why some natural exon skipping variants act dominantly and others
recessively is unknown. In general, and comparable with dominant
glycine substitutions,37 dominant skipping exons are located closer
to collagenous imperfections than recessive ones and are found
more toward the end of the THD. However, location does not seem
to be the only reason, because two of the recessive exons are also
located near collagenous imperfections, and ﬁve are located near
the end of the THD. A possible explanation as to why some skipped
exons act dominantly whereas others act recessively could be the ratio
between exon-skipped alleles and wild-type alleles. Analogous to the
ﬁnding that the wild-type versus mutant allele ratio determines the
level of THD instability and consequently the phenotype,38 it is
conceivable that the relative amount of exon-skipped type VII
collagen present is also crucial in determining its phenotypic effect.
Unfortunately, it is not possible to study this hypothesis in detail
because the level of exon skipping was quantiﬁed at the RNA level
for only one of the exon skipping variants (variant 9 in Table 1).
The heterozygous variant c.6215delA resulted in a 0.73:1 exon 74-
skipped to wild-type type VII collagen mRNA ratio and the DDEB-
pr phenotype.
Intra-epidermal cytoplasmic retention of type VII collagen has been
described for several variants and is believed to be the result of
disturbed triple-helix formation. For instance, it has been reported
for several glycine substitutions leading to DDEB, like the p.Gly2037-
Glu glycine substitution,39 bullous dermolysis of the newborn,40 and
RDEB-inversa.41 The fact that we observed cytoplasmic retention in
all four dominant exon skipping cases and in one of the three recessive
skipping cases indicates that exon skipping also disturbs normal triple-
helix formation because of a dominant-negative effect. Hence it makes
sense that the dominant phenotypes due to natural exon skipping fall in
the range seenwith glycine substitutions. Intra-epidermal retention in a
skin biopsy of a DEB patient with unknown genetic cause could thus
also point to in-frame exon skipping and should warrant RNA analysis
if no glycine substitution is found.
Clearly, exon 87 is a hotspot for dominant natural exon skipping. Ten
different variants that induce skipping of exon 87 were identiﬁed, of
which 6 are located in the intron 87 splice donor site, indicating that
this is a weakly deﬁned exon. It has been shown that variants in donor
sites are more likely to disrupt splicing, and that the lack of cryptic
splice donor signals within 50 bp downstream of splice donor sites in-
creases the likelihood of skipping the entire exon.33 Using Human
Splicing Finder42 (http://www.umd.be/HSF3/), we examined exons
86, 87, and 88 (Figure S3) for such cryptic splice donor sites. Indeed,
no cryptic splice donor sites were predicted downstream of the splice
donor site of exon 87, whereas three and seven sites were found for
exons 86 and 88, respectively. The lack of these cryptic splice donor
sites in intron 87 may explain why so many variants lead to complete
skipping of exon 87.
Pruritus is strongly linked to disorders of the BMZ, including EB. An
association has been suggested between heterozygous skipping of
exon 87 and pruritus.23 Indeed, six patients with exon 87 skipping
www.moleculartherapy.orgvariants were reported to have the DDEB-pr phenotype. One other
case of DDEB-pr was found to have an exon skipping mutation,
exon 71. Four of the seven families originated from Southeast
Asia,16,22,25,26 a geographic region where pruritic diseases are more
common in general.43 Whether there exists a causative link between
exon skipping and DDEB-pr, and what the underlying mechanism
would be, or that this association is merely due to a combination of
other genetic and environmental factors, cannot be answered from
this review and needs further study.
RDEB-gen intermed is still a severe phenotype in itself and improving
a RDEB-gen sev phenotype to this level is still far from curing RDEB.
However, we believe that preventing the development of the RDEB-
gen sev phenotype would be amajor improvement for several reasons:
reduced cancer risk, a longer lifespan, a reduced risk and slower pro-
gression of pseudosyndactyly and esophageal strictures, and thus
improved quality of life.
In conclusion, exon skipping therapy for DDEB patients seems un-
likely to beneﬁt patients and may theoretically even worsen their
phenotype, whereas such therapy for RDEB patients has the poten-
tial to improve the RDEB-gen sev phenotypes, particularly caused
by bi-allelic null mutations, and push the clinical outcome
toward the milder RDEB-gen intermed phenotype. The focus of
developing exon skipping as a therapeutic approach should
therefore be on RDEB-gen sev patients because of COL7A1 null
variants.
MATERIALS AND METHODS
Molecular Analysis of Patient Material
Molecular analysis at the DNA and protein level was performed as
previously described.2 In short, DNA, isolated from peripheral blood
lymphocytes, was subjected to variant analysis of the COL7A1 gene
(GenBank: NM_000094.3) by direct Sanger sequencing. Protein
expression was examined by IF microscopy on 4-mm cryosections
using monoclonal LH7.2 antibody (Abcam, Cambridge, UK) and
analyzed on a Leica DMRA microscope (Wetzlar, Germany).
Randomly primed two-step RT-PCR was performed on RNA isolated
from 40-mm skin cryosections, using PCR primers that bind to exons
at least two exons upstream or downstream of the variant, in order to
be able to identify potential skipping of multiple exons.
Dutch EB Registry and Literature Review
To gain a complete picture of COL7A1 variants that cause in-frame
exon skipping, we scrutinized the Dutch EB registry, the DEB registry
(https://www.deb-central.org), and the literature on DEB and
COL7A1. “COL7A1,” “COL7A1 splicing,” and “COL7A1 exon skip-
ping” were used as queries in a search of NCBI PubMed (https://
www.ncbi.nlm.nih.gov/pubmed). All variants that led to skipping of
complete exons were included, regardless of the presence of addi-
tional splice variations. We excluded variants that led only to splice
patterns other than in-frame exon skipping (i.e., skipping of an
out-of-frame exon, in-frame or out-of-frame deletions or insertions
not involving an entire exon, or partial or full intron retention).Conﬁrmation of exon skipping at the RNA level was a prerequisite
for inclusion. Reported expression levels were uniﬁed into normal/
slightly reduced/reduced/strongly reduced/absent.
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